Fig. 3.

Pretreatment with aldosterone (Aldo) during a 1-wk induction period (I) cross-sensitized the hypertensive response elicited by a slow pressor infusion of ANG II (120 ng·kg⁻¹·min⁻¹ sc) administered during a 2-wk expression period (E). The induction period was followed by a 1-wk, no-treatment delay period (D) before the start of the expression period (E). During the induction period Aldo (750 ng/h sc; groups 1, 3, and 4) or saline (S; group 2) was administered. Animals in group 4 received RU283, a mineralocorticoid receptor antagonist, (1.1 μg/n icv) along with the subcutaneous Aldo treatment during the induction period. RU28318 blocked cross-sensitization of the hypertensive response. *P < 0.05 vs. baseline or I-Aldo+E-S. #P < 0.05 vs. I-S+E-ANG II, or I-Aldo/icv RU28318+E-ANG II. [With permission from Wolters Kluwer Health, Hypertension, Sensitization of slow pressor angtiontensin II (Ang II)-initiated hypertension: induction of sensitization by prior Ang II treatment, by Xue B, Zhang Z, Roncari CF, and Johnson AK, vol. 60, 2012 (201)].